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ABSTRACT
Objective: Smoking cessation and relapse prevention during
and after pregnancy reduces the risk of adverse maternal and
infant health outcomes, but the economic evaluations of such
programs have not been systematically reviewed. This study
aims to critically assess economic evaluations of smoking
cessation and relapse prevention programs for pregnant
women.
Methods: All relevant English-language articles were identi-
ﬁed using PubMed (January 1966–2003), the British National
Health Service Economic Evaluation Database, and reference
lists of key articles. Economic evaluations of smoking cessa-
tion and relapse prevention among pregnant women were
reviewed. Fifty-one articles were retrieved, and eight articles
were included and evaluated. A single reviewer extracted
methodological details, study designs, and outcomes into
summary tables. All studies were reviewed, and study quality
was judged using the criteria recommended by the Panel on
Cost-Effectiveness in Health and Medicine and the British
Medical Journal (BMJ) checklist for economic evaluations.
Results: The search retrieved 51 studies. No incremental
cost-effectiveness studies or cost-utility studies were found. A
narrative synthesis was conducted on the eight studies that
met the inclusion criteria. Roughly one-third employed cost–
beneﬁt analyses (CBA). Those conducting CBA have found
favorable beneﬁt–cost ratios of up to 3:1; for every dollar
invested $3 are saved in downstream health-related costs.
Conclusions: CBA suggests favorable cost–beneﬁt ratios for
smoking cessation among pregnant women, although cur-
rently available economic evaluations of smoking cessation
and relapse prevention programs for pregnant women
provide limited evidence on cost-effectiveness to determine
optimal resource allocation strategies. Although none of
these studies had been performed in accordance with Panel
recommendations or BMJ guidelines, they are, however,
embryonic elements of a more systematic framework. Exist-
ing analyses suggest that the return on investment will far
outweigh the costs for this critical population. There is sig-
niﬁcant potential to improve the quality of economic evalu-
ations of such programs; therefore, additional analyses are
needed. The article concludes with ideas on how to design
and conduct an economic evaluation of such programs in
accordance with accepted quality standards.
Keywords: economic evaluations, pregnant women, relapse
prevention, smoking cessation, systematic review.
Introduction
Smoking during pregnancy is an important public
health and economic issue. It increases the risk of
preterm membrane rupture, placental abruption, pla-
centa previa, stillbirth, low birth weight, sudden infant
death syndrome (SIDS) [1], cleft palates and lips, and
childhood cancers [2]. A majority of women who
smoke (60–67%) do not stop smoking when they learn
they are pregnant [3]. While evidence from several
studies suggests that smoking cessation programs
targeted at pregnant women—especially augmented
psychosocial interventions [2] can reduce smoking
during and after pregnancy and should be offered [2],
it is important to know whether such programs are
cost-effective. The tobacco control research commu-
nity is increasingly interested in the economic, as well
as the clinical, implications of interventions designed
to reduce tobacco use, especially among critical popu-
lations such as pregnant women.
Although they have the potential to be cost-effective
if they reduce smoking and thus the incidence of low-
birth-weight (LBW) babies, perinatal deaths, and physi-
cal, cognitive, and behavioral problems during infancy
and childhood, economic evaluations of such programs
have not yet been subjected to systematic review.
Policymakers want to know which smoking cessa-
tion and relapse prevention programs for pregnant
women are both effective and cost-effective—and
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whether such a program is worth implementing or
covering as compared to other interventions or pro-
grams in, for example, an insurance package or as a
guaranteed beneﬁt as part of a national health service
when resources are scarce. Therefore, high-quality evi-
dence for clinical effectiveness and cost-effectiveness
would facilitate resource allocation. This article sys-
tematically reviews and critically assesses economic
evaluations of smoking cessation and relapse pre-
vention programs among pregnant women. It also
highlights the opportunity for research ﬁndings on eco-
nomic evaluations to provide the inputs for developing
policies to support programs that help pregnant
women quit and remain abstinent. In general, there are
four different types of economic evaluations: cost-
minimization analysis (CMA), cost-effectiveness analy-
sis (CEA), cost–beneﬁt analysis (CBA), and cost-utility
analysis (CUA) (see Table 1). In comparing two inter-
ventions designed to address the same health problem,
CMA searches for the least costly alternative that pro-
duces the same health beneﬁt. CEA by contrast com-
pares the per unit effect with the per unit cost on an
incremental basis of two different health interventions
and CBA measures both the costs and consequences of
two or more alternative interventions in terms of the
potential dollars gained or saved compared to the
dollars invested in the intervention. Lastly, CUA is a
type of CEA that employs utilities (e.g., quality-
adjusted life-years or QALYs) as the outcome measure
to compare and evaluate two or more interventions
incrementally. CUA attempts to translate the health
outcomes of all interventions into a single outcome
measure (e.g., QALYs) in efforts to compare the added
value of one program versus another on the same
outcome scale.
Although a review of the effectiveness of pregnancy-
related smoking cessation and relapse prevention pro-
grams was performed during the creation of Treating
Tobacco Use and Dependence, a US Department of
Health and Human Services Clinical Practice Guide-
line [2], to our knowledge this is the ﬁrst systematic
review of the economic evidence on such programs.
Methods
Search Strategy
Strategies for identifying and selecting economic evalu-
ations for systematic review are described elsewhere
[5–13], and our search was consistent with those
approaches. We searched PubMed (inception, January
1966–July 2003) and the British National Health
Service Economic Evaluation Database (NHS EED)
(http://www.york.ac.uk/Institute/crd/nhsdhp.htm) for
English-language articles. We combined the search
terms smoking cessation or relapse prevention with
pregnant women and with cost or cost analysis or cost
effectiveness or cost beneﬁt or cost utility or economic
evaluation or economic or QALY or quality-adjusted
or cost per life year, trying different combinations of
these key words for both databases. We also manually
searched the reference lists of retrieved articles and
Treating Tobacco Use and Dependence [2] and selected
relevant articles for inclusion. This search resulted in
51 articles related to the search terms. Due to the
dearth of literature in this area and because one of our
key aims was to assess quality, we originally included
all 51 relevant studies identiﬁed by our literature
search. This sample included a number of different
types of economic evaluations (Table 1) and not just
cost-utility analyses, as recommended by the Panel on
Cost-Effectiveness in Health and Medicine [5]. Exclud-
ing studies that were not CEA or CUA would have left
us with few studies to assess.
After retrieving the original set of 51 articles, we
screened for studies that met the following criteria: 1)
addressed the identiﬁed question; 2) involved original
economic analysis (not just CEA, see Table 1); and 3)
reported an appropriate outcome metric (an appropri-
ate health outcome such as life expectancy or quit rates
even if it was not QALYs) [2]. We coupled these crite-
ria with the standard inclusion criteria for economic
evaluation studies presented in the Guide to Commu-
nity Preventive Studies [9], which require studies to use
one of the four analytical methods recommended by
Drummond et al. (Table 1) [7]. Employing these crite-
ria allowed us to select studies that: provided sufﬁcient
detail on methods and results; were primary studies
rather than guidelines or reviews; were published
within an appropriate time frame; were written in
English; and were conducted in one or more Estab-
lished Market Economies [9]. The eight studies that
met these inclusion criteria were abstracted by a single
reviewer; consensus regarding inclusion or exclusion
was not relevant to our purposes.
Data Extraction
The data extracted from each full article is delineated
in Table 2. One trained person with graduate educa-
tion in decision analysis and cost, cost–beneﬁt, cost-
effectiveness, and cost-utility analyses read every
article and extracted and analyzed the data. Data
extraction was based on the checklist for reporting
reference-case cost-utility analyses recommended by
the Panel on Cost-Effectiveness in Health and Medi-
cine [5] and on guidelines developed for economic
Table 1 Types of economic evaluation*
1. Cost-Minimization Analysis: searches for the least costly alternative
producing same health beneﬁt
2. Cost-Effectiveness Analysis: compares per unit effect with per unit
cost on an incremental basis
3. Cost–Beneﬁt Analysis: measures both the costs and consequences of
alternatives in dollars
4. Cost-Utility Analysis: type of cost-effectiveness analysis that employs
utilities (e.g., quality-adjusted life-years) to evaluate a program
*Adapted from Drummond et al. [4].
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submissions to the British Medical Journal (BMJ). It
was also consistent with the data auditing form devel-
oped by researchers at the Harvard Center for Risk
Analysis (available at: http://www.hsph.harvard.edu/
cearegistry) (See Table 3). The Panel’s checklist and
BMJ guidelines were also used as criteria for evaluat-
ing the quality of the economic studies.
Data Synthesis
Because of the heterogeneity of study types and our
goal of assessing the quality of economic evaluations,
we used narrative synthesis [14] rather than formal
meta-analysis. In contrast to meta-analysis, narrative
synthesis does not include quantitative synthesis. This
review summarizes the type, statistical signiﬁcance,
and distribution of a program’s effectiveness and costs.
Methodological and intervention differences among
studies prevented us from adjusting the original study
results to identify the conclusions that would have
been obtained, and had the study followed the stan-
dards recommended [9], for example, by the Panel
(e.g., inclusion of the reference case) [5]. Types of
smoking cessation and relapse prevention programs
ranged from “usual care” (an intervention lasting less
than 5 minutes and consisting of a recommendation to
stop smoking with provisional self-help materials and
sometimes a referral to a stop-smoking program) to
extended psychosocial programs (more intensive coun-
seling) [2]. Meta-analysis of program’s effectiveness
has found the latter to be more effective [2].
Results
Literature Search: Identiﬁcation of Economic Analyses
Our search identiﬁed 51 potentially relevant studies.
Figure 1 delineates a ﬂow chart of the study selection
process. A study investigator reviewed the titles and
abstracts to determine whether an article contained an
economic analysis. This initial review excluded articles
that were clearly not economic evaluations or were
clearly not related to our subject of interest, as noted
by the criteria described above. For example, a search
that included the terms costs, smoking cessation, and
pregnant women identiﬁed a number of studies on the
relationship between the costs of neonatal health care
and maternal smoking during pregnancy. Although
such cost estimates would normally be one component
of an analysis of the societal beneﬁts of smoking ces-
sation programs among pregnant women, the studies
we identiﬁed did not systematically compare costs and
beneﬁts or employ one of the four standard types of
economic evaluation (Table 1). Of the articles retrieved
and reviewed, eight met the inclusion criteria.
Study Descriptions
Table 4 summarizes the key characteristics of the eco-
nomic analyses we selected, especially their underly-
ing assumptions, methodologies, and conclusions.
Although none of these eight studies was an incremen-
tal CEA or CUA, or expressed beneﬁts in QALYs
gained or saved, a few studies did express beneﬁts in
terms of days of life or life-years gained. Moreover, the
studies differed signiﬁcantly in terms of economic
study type and main assumptions. The narrative below
identiﬁes some ways in which the main assumptions
differed and how the investigators arrived at both dif-
ferent and overlapping conclusions about the eco-
nomic impact of smoking cessation programs among
pregnant women. The variation in methods and
Table 2 Data extracted from included articles
1. Author
2. Years of study
3. Topic and study question
4. Setting
5. Type of economic analysis
6. Year of publication
7. Intervention type
8. Health outcomes
9. Methods used to deﬁne effectiveness and preferences: time trade-off,
standard gamble or rating scale, source of weights
10. Resource and cost estimates: net costs, gross- or micro-costing, year,
currency
11. Inclusion of original analyses
12. Study perspective
13. Description of comparator intervention
14. Study assumptions
15. Study type and design: clinical trial, observational study, decision
analytical model
16. Modeling assumptions
17. Variable estimates
18. Discounting
19. Sensitivity analyses performed: for costs, effectiveness, preference
weights, discount rate
20. Funding source
21. Comparison with other economic evaluations
Table 3 Criteria for assessing quality of economic evaluations*
Framing
• Comparator intervention
• Study perspective
• Modeling assumptions and diagram
• Discounting
Costs
• Reporting of direct and indirect costs
• Reporting of net costs
• Costing source
• Costs reported in single year
Effects
• Health outcomes stated
• Preferences and source stated
Results
• Incremental cost-effectiveness ratios
• Sensitivity analyses
Discussion
• Study limitations
• Comparison with other studies
*From the checklist for reporting reference-case cost-utility analyses recommended
by the Panel on Cost-Effectiveness in Health and Medicine and guidelines for eco-
nomic submissions to the BMJ; also consistent with the data auditing form developed
by researchers at the Harvard Center for Risk Analysis.
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reporting offer a wide array of research ﬁndings for
interpretation. Future reviews would beneﬁt from
greater consistency in methods and reporting across
studies.
Assessing Economic Evaluation Quality
Methods
Analysis and model type. All eight studies involved
some sort of economic analysis although the study type
varied considerably. Half of the studies [15,17,18,20]
employed a CBA, measuring both the costs and con-
sequences of alternatives in dollars, though the CBA
types performed were closer to cost-saving analyses
than traditional CBA methods (e.g., valuing a life-year
saved in monetary terms) in that they estimate savings
in health-care expenditures resulting from not
smoking. Two studies employed CEA to estimate the
“break-even” cost for a given quit rate [19,21], and
one employed CEA to estimate the cost per percentage
that quit [16]. One study used CEA to estimate the cost
per SIDS death averted [22]. In terms of study design
and modeling, three studies [16,17,20] were random-
ized controlled trials, one was a nonrandomized com-
parison [15], two employed decision trees to model
costs and consequences [19,21], and a third used con-
ditional logistic regression analysis to estimate the con-
sequences of smoking cessation (in terms of SIDS risk)
[22]. One study did not specify the model type, but did
use estimates from the literature [18].
Framing
Study perspective and time horizon. Two of the
studies reviewed reported results from the societal per-
spective [18,22]. Other points of view included agency
[16,20], health maintenance organization (HMO)
[15,17], and program [19], while one study [21] did
not specify a perspective in their analysis. Although,
according to the Panel, employing any perspective
other than societal limits the generalizability of the
results and weakens the strength of the study ﬁndings,
alternative perspectives from these studies compliment
the societal point of view in providing useful informa-
tion to program, insurance, and agency representa-
tives. In terms of the time horizon, three studies ended
at the end of pregnancy [16,21] or postdelivery [19],
while two studies extended through the infant’s ﬁrst
year of life [15,17] and the remaining three studies
extended 35 years [18] or a lifetime [20,22] interven-
tion (comparator).
Intervention types varied across studies, with
several including advice/counseling supplemented with
written materials [16–18,20]. These studies included
programs with a 15-minute session with a health coun-
selor, social support, and written materials [20]; a
hypothetical model program consisting of a 15-minute
46 Articles Retrieved for More 
Detailed Evaluation 
5 Articles Excluded for Lack of Evaluation of SC/RP Programs 
51 Potentially Relevant Articles 
Identified and Screened for 
Retrieval
38 Excluded (No Economic Analysis of SC/RP Programs) 
     13 Review Articles 
       4 Highlight Effectiveness of SC Interventions 
       3 Report Tobacco Treatment Guidelines and Strategies 
       3 Assess Benefits or Services for Medicaid Recipients  
       3 Estimate Costs Associated with Smoking        
       2 Propose New SC Interventions 
       2 Describe Coverage of Tobacco Dependence Programs 
       2 Describe Factors Associated with SC During Pregnancy       
       2 Comparisons of SC Programs 
       1 Qualitative Study of Barriers to SC 
       1 Programs for Healthy Start Projects 
       1 Introduction Article 
       1 With No Comparable Health Outcomes 
8 Studies Included 
Figure 1 Flow chart of the study selection
process. RP, relapse prevention; SC, smoking
cessation.
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counseling session, two follow-up phone calls, and
instructional materials [18]; brief counseling and eight
booklets mailed weekly [17]; and quit advice supple-
mented with either an American Lung Association
manual or a pregnancy-speciﬁc manual [16]. Three
studies looked at hypothetical prenatal smoking cessa-
tion programs, but did not specify the components of
these programs [19,21,22]. One study involved an
8-week home-correspondence program [15]. Half
of the studies reviewed analyzed an alternative
[15–17,20], comparing interventions to a control
group that received usual or standard care, typically
less than 5 minutes of counseling plus materials. The
other studies did not identify a comparator
[18,19,21,22].
Discounting. Two studies indicated a discount rate,
ranging from 4% in one study [18] to 5% in another
[22]. In all other studies, discounting was either not
applicable [15,17,21] or not reported [16,19,20].
Costs
Reporting of direct and indirect costs. The cost com-
ponents of the cost analysis varied widely across
studies. Two studies used hospital charges as proxies
for costs [19,21]. For both studies [19,21], direct
medical charges related to hospitalization at delivery
were compared; one of these studies [21] used a charge
cost deﬂator [5]. One study estimated costs of $45 for
a hypothetical “typical” smoking cessation program
based on data from other analyses in the ﬁeld [22].
Windsor et al. [16] included direct programs costs,
such as personnel and educational materials, and
excluded costs related to facilities, other supplies, and
patient time because of similarities in these costs across
groups. Marks et al. [18] incorporated direct program
costs (for counseling, follow-up calls, and materials),
but also included training and overhead costs. Indirect
costs were not included, nor were potential maternal
health beneﬁts and associated costs. Costs per LBW
infant for neonatal intensive care were derived from
the Ofﬁce of Technology Assessment and adjusted to
1986 dollars, as was the lifetime cost of special services
from 1 to 35 years because of low birth weight in this
study. For the remaining two studies [15,17], one
included staff time, overheads, materials costs, and
cost savings attributable to the reduced number of
LBW babies from an HMO perspective [17], and the
other included staff salaries, development and over-
head costs, materials costs, and the reduction in hos-
pital costs associated with normal infant birth weight
[15].
Costing source and reporting. Reporting costs in a
single year from a speciﬁed source is crucial for com-
parison across studies and generalizability of study
results. Nearly all studies speciﬁed costing source
[15–18,20–23], with only one study not reporting the
source of costs [19]. The costing sources reported
included program records [16], program and hospital
records [15,17], randomized controlled trial [20],
Ofﬁce of Technology Assessment [18,20], rough esti-
mates [18], rough estimates combined with the use of
a decision tree to model and estimate costs [21], and
assumed costs from prior studies [22]. Slightly more
than half of the studies reviewed reported base costs in
a single year [18–22], while one study reported costs
over a 2-year span [15], one reported costs over a
3-year span [17], and one study did not report a base
year for costs [16].
Effects
Health outcomes. The health outcomes and beneﬁts
measured varied across studies. Most studies included
a measure of either smoking status [15], quit rates
from primary studies [16,17,20], or quit rates obtained
from the literature [18,19,21]. Several studies also
employed infant outcomes, including LBW birth pre-
vented [15,17–21], number of preterm births reported
[15,19], perinatal death prevented [18], neonatal
intensive care unit (NICU) costs prevented [18], life-
year gained [18] or saved [22], SIDS death averted
[22], and long-term disability prevented [18]. One
study assessed maternal health outcomes related to
pregnancy, abruptio, hemorrhage, previa, and pre-
eclampsia [19]. No studies reported outcome in terms
of QALYs [5].
Results
The results from all studies indicated favorable out-
comes for intervention methods aimed at reducing
smoking during pregnancy and, subsequently, improv-
ing maternal and infant health outcomes. The litera-
ture reviewed herein suggests signiﬁcant net positive
economic beneﬁts of prenatal smoking cessation inter-
ventions. Half of the studies reported results as cost–
beneﬁt ratios [15,17,18,20]. Two studies reported
overall beneﬁt–cost ratios of 2:1 (for the program) [15]
and 3:1 (to the HMO) [17]. These results suggest that
from a program perspective $1 invested yields cost
savings of nearly $2. Similarly, the results of the HMO
study suggest that the returns on investment are even
greater from a provider’s perspective, $3 saved
for every dollar spent. One study noted a beneﬁt–cost
ratio of 3.3:1 for preventing NICU costs and 6.6:1 for
preventing long-term disability [18], suggesting
smoking cessation before the end of pregnancy pro-
duces signiﬁcant cost savings from the prevention of
neonatal complications and long-term disability.
Another study reported a range of beneﬁt–cost ratios
from 1.8:1 (low estimate) to 4.6:1 (high estimate) and
a cost-saving range of $365,728 to $968,320 [20].
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One study found estimates of cost per percent that quit
ranging from $51 to $118 [16], while another study
(from a national perspective) estimated the costs of
preventing a LBW birth ($4000) and a perinatal death
($62,542) [18]. The total cost per life-year gained from
this study was $2934 [18]. Two studies estimated the
“break-even” costs per pregnant woman [19,21] for
different quit rates, resulting in a range of $10 to $237
per pregnant woman in one study [19] and of $14 to
$135 in another study [21]. A ﬁnal study reported a
cost per SIDS death averted of $210,500 and a cost per
life-year saved of $11,000 [22].
Sensitivity analyses. Several studies [16,18–21] con-
ducted sensitivity analyses. Two studies did not employ
sensitivity analyses [15,17], one did not specify if sen-
sitivity analyses were conducted [22]. Most studies
conducted sensitivity analyses on quit rates [16,18–
21], and some analyzed intervention costs [16,20] and
hospital charges [19]. Parameters related to infant
health such as risk [18,20] or probability of low birth
weight, proportion of LBW infants requiring NICU
care and relative risk of perinatal death, were also
examined [18]. One study analyzed the ranges of the
percentage of women smoking at baseline and of the
probability of maternal complications [19].
Discussion
This review of the literature on economic evaluations
of smoking cessation and relapse prevention programs
among pregnant women reveals a dearth of studies on
the subject and provides justiﬁcation for further
research support in this critical public health area.
Although none of the studies were performed entirely
in accordance with Panel recommendations or BMJ
guidelines (e.g., none employed incremental CEA or
CUA), numerous studies included certain aspects of
these guidelines and provided useful research ﬁndings
on the value of prenatal smoking cessation to women,
infants, providers, and society at large. Thus, portions
of each study may be used as an example for future
analyses. It is also worth noting that, since most of the
studies we reviewed were published before the devel-
opment of the guidelines for conducting and reporting
economic evaluations, one would expect some diver-
gence between recommended guidelines and study
results, further bolstering efforts of the mid-1990s to
standardize economic evaluations to reduce uncer-
tainty among researchers, reviewers, and journal
editors about methods and reporting practices. Stan-
dards established by the Panel, the Cochrane Group,
the BMJ, and others are likely to improve the quality
and consistency of future economic evaluations in
health and medicine.
Thus, while differences in the design, reporting, and
description of economic evaluation and in model
assumptions, data deﬁnition and estimation, discount
rates and perspectives, to a certain extent limit our
ability methodologically to draw head-to-head conclu-
sions about the most effective and cost-effective strat-
egies, together these studies offer distinct insights into
the value of reducing smoking among pregnant
women.
For example, despite the fact that reporting prac-
tices of economic analyses varied widely, most studies
in this ﬁeld have employed CBA and have found favor-
able cost–beneﬁt ratios, even when maternal beneﬁts
are excluded. Moreover, estimates of program costs
appear to be based on similar assumptions and to be
similar. It is unclear why CBA has been the method of
choice [24], and it is worth noting that the types of
CBA performed in the studies reviewed here are not
traditional (e.g., valuing a life-year saved in monetary
terms) but are more akin to cost-saving analysis in that
they estimate savings in health-care expenditures
resulting from not smoking. It appears that the litera-
ture has focused on these types of studies because of
the interest and ease of estimating hospital costs (pri-
marily costs of neonatal intensive care) associated with
not quitting smoking during pregnancy.
The studies that aimed to estimate the break-even
cost of smoking cessation programs demonstrated that
such programs pay for themselves because, by and
large, they save more than they cost. Many studies did
not, however, adopt the societal perspective, nor did
they include all relevant costs (e.g., training costs),
suggesting these research ﬁndings are conservative esti-
mates of potential savings. Although it is difﬁcult to
say whether such programs produce incremental
health gains (at the margin) and to assess the marginal
cost of those gains (because few studies used compa-
rable outcome measures [health gains measured in life-
years saved or QALYs saved]), resource savings as an
outcome is relevant for analyzing the ﬁnancial invest-
ment of prevention programs.
In summary, prenatal smoking cessation offers both
health and economic beneﬁts for women, infants, pro-
viders, and society. When women quit smoking by the
ﬁrst trimester of their pregnancy, for example, their
infants are likely to have the same body weight as
infants of nonsmokers and they signiﬁcantly reduce
the risk of intrauterine growth retardation. Prenatal
smoking cessation programs are also relatively inex-
pensive on average, with costs in some cases as low as
$25 per person for brief counseling. Combining costs
and beneﬁts reveals highly favorable beneﬁt–cost
ratios (of up to $6 saved for every dollar invested),
signiﬁcant cost savings (of up to $1,000,000), and
modest costs for health gain, ranging from $100 per
percent that quit to $4000 per LBW birth prevented to
$63,000 per perinatal death prevented to $11,000 per
life-year saved and $210,000 per SIDS death averted.
By any measure, such programs compare favorably to
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more than 80% of clinical preventive services that are
not cost-saving; in some cases, the cost per life-year
saved of these services can range from $165,000 to
$450,000. These ﬁndings could be considered by
state public health departments, Medicaid agencies,
employers, and health insurance plans (including
managed care) to provide smoking cessation beneﬁts
and work with providers on screening, counseling, and
behavioral interventions for tobacco use.
A ﬁnal note on methodology, while such limitations
hinder comparisons among programs, they also repre-
sent an opportunity for future analyses to better adhere
to sound and consistent methodologies as recom-
mended by the Panel and the BMJ. A lack of economic
studies is common in health and medicine, however,
especially in the area of community prevention services
[25]. Thus, even the limited number of economic studies
on smoking cessation among pregnant women,
although not surprising, signal the value of such studies.
In some respects, however, these results are some-
what surprising, given the general trend toward more
systematic reporting in the evaluation of tobacco-
related interventions [26]. There has also been a long-
standing emphasis in health economics toward
standard reporting of study assumptions and basic cost
and health outcomes [4].
Our analysis has several limitations. First, it is
restricted to a speciﬁc intervention type (smoking ces-
sation and relapse prevention) and therefore does not
include the economic evaluation of other types of pro-
grams that aim to reduce the health risks to mothers
and infants during and after pregnancy. Second, as
with any review that uses key words in a literature
search, it may have missed some relevant studies.
Third, an in-depth assessment of the merits of all clini-
cal and economic assumptions and research methods
was not made. As noted above, the considerable het-
erogeneity among study types, methods, main assump-
tions, interventions, and outcomes precluded a formal
meta-analysis and the use of strict quality criteria
relating solely to cost-utility analyses. Therefore, we
included all studies that met our basic inclusion criteria
and derived no weights to assess the signiﬁcance or
quality of any individual study. The lack of compara-
bility across studies limits our ability to determine
speciﬁc public policy implications.
Despite these challenges, efforts to sort out some of
the ﬁner methodological challenges in both the cost
and effectiveness elements of CEA will eventually lead
to more uniformity in reporting. For example, efforts
to enumerate cost categories and determine and
measure health beneﬁts (in terms of life-years gained)
will eventually improve the generalizability and com-
parability of the results of CEA. In combination with
established standards, such efforts will help in the
development of an analytic framework for making
future studies more comparable.
In conclusion, ideal studies of economic evaluations
of smoking cessation and relapse prevention programs
for pregnant women would prospectively apply stan-
dardized methods noted herein. Characteristics one
would be looking for in such a study would include an
economic evaluation planned prospectively alongside a
randomized clinical trial in which all inputs consumed
in the interventions would be measured and valued
alongside the clinical trial to enhance the reliability and
validity of intervention costs. Costs collected would
include those necessary to reproduce the intervention
in a nonresearch setting and such inputs would likely
include time spent with clients for intervention delivery
and follow-up and materials. The cost analysis would
be extended to the societal perspective by including cost
savings for neonatal intensive care, chronic medical
conditions, and acute conditions during the ﬁrst year of
life and cost savings for maternal health care (cardio-
vascular and lung diseases). The primary outcomemea-
sures would be quit and relapse rates measured during
the trial and extended to the societal perspective by
converting such rates into life-years saved and QALYs
saved. Future beneﬁts would be discounted at a 3%
annual rate as recommended by the Panel on Cost-
Effectiveness in Health andMedicine. CEAs employing
these data would then be performed from the societal
perspective to estimate incremental cost-effectiveness
ratios, expressed as net resource cost per life-year
gained or QALY gained. Sensitivity analysis performed
by varying important parameters singly, and in combi-
nation, through clinically meaningful ranges would
examine the robustness of the ratio estimates. We are
publishing one such study that meets these criteria [27].
The studies reviewed in this article might therefore be
seen as useful embryonic elements of a more systematic
framework for conducting meaningful and useable
analyses of smoking cessation and relapse prevention
programs for pregnant women.
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